News
A new “fluid biopsy” technique that could identify patients at high risk of a heart attack by identifying specific cells as markers in the bloodstream has been developed by a group of researchers at The Scripps Research Institute (TSRI).
January 15, 2014
Feature
A new magnetic resonance imaging (MRI) method to map creatine at higher resolutions in the heart may help clinicians and scientists find abnormalities and disorders earlier than traditional diagnostic methods.
January 15, 2014
Feature
Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp.
January 14, 2014Sponsored Content
Feature
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
June 17, 2025
Feature
Edwards Lifesciences Corp. announced that it received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of the Sapien 3 transcatheter aortic heart valve in the treatment of intermediate risk patients with severe symptomatic aortic stenosis.
January 14, 2014
Technology
MediValve Ltd. announced that it has received clearance of a Pre-Marketing Notification Application (510(k)) from the U.S. Food and Drug Administration (FDA) for its acWire Guidewire.
January 14, 2014News
A clinical trial found that Xa inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).
January 14, 2014Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News
CVRx Inc. announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug-resistant hypertension.
January 10, 2014
News
In a preclinical study, researchers from Boston Children's Hospital, BWH and Massachusetts Institute of Technology (MIT) developed a bio-inspired adhesive that could rapidly attach biodegradable patches inside a beating heart in the exact place where congenital holes in the heart occur.
January 09, 2014
Feature
Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board (DSMB) concluded that there were no safety concerns in the study.
January 09, 2014Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News
SunTech Medical, a Halma company that provides noninvasive blood pressure monitoring products and technologies, has signed a cooperation contract with Corscience GmbH and Co. KG, medical engineering company that specializes in cardiovascular applications, Erlangen, Germany.
January 09, 2014
Feature
Topera Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest generation of its 3D Mapping System.
January 09, 2014
News
iRhythm Technologies announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the company's ZIO Service significantly increased detection of cardiac arrhythmias, compared to use of the traditional Holter monitor.
January 08, 2014Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Technology
Biodex Medical Systems Inc. introduced its line of ultrasound tables, which feature redesigned optional side rails that tuck underneath the table when not in use to allow clear access to the tabletop.
January 08, 2014
News
A report by MarketsandMarkets analyzes and studies the major technology and market drivers, restraints and opportunities in North America, Europe, Asia and Rest of the World.
January 08, 2014News
Vasomedical Inc. announced that the FDA issued its final order Dec. 30, 2013, reclassifying external counterpulsation (ECP) devices for treatment of chronic stable angina for patients that are refractory to antianginal medical therapy and without options for revascularization from class III to class II (special controls).
January 07, 2014